Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 1;35(8):1201-1208.
doi: 10.1097/QAD.0000000000002871.

To dose-adjust or not to dose-adjust: lamivudine dose in kidney impairment

Karam Mounzer  1 , Laurence Brunet  2 , Christina M Wyatt  3 , Jennifer S Fusco  2 , Vani Vannappagari  4 , Allan R Tenorio  4 , Mark S Shaefer  4 , Leigh Ragone  4 , Ricky K Hsu  5   6 , Gregory P Fusco  2
Affiliations

To dose-adjust or not to dose-adjust: lamivudine dose in kidney impairment

Karam Mounzer et al. AIDS. .

Abstract

Objectives: To assess the risk of adverse diagnoses and laboratory abnormalities associated with a 300 or 150 mg daily dose of lamivudine (3TC) initiated by people with HIV (PWH) with an estimated glomerular filtration rate (eGFR) between at least 30 and 49 ml/min per 1.73 m2 or less.

Design: Longitudinal study based on electronic health records of 539 PWH with eGFR between at least 30 and 49 ml/min per 1.73 m2 or less from the Observational Pharmaco-Epidemiology Research and Analysis (OPERA) cohort.

Methods: Common unintended effects of 3TC were evaluated as composite outcomes. We estimated the incidence (univariate Poisson regression) and association between dose and incident composite outcomes (multivariate Poisson regression) among PWH without the relevant diagnoses or laboratory abnormalities at 3TC initiation.

Results: PWH initiating 150 mg 3TC had higher HIV RNA, lower eGFR, and more comorbidities than those initiating 300 mg 3TC. The prevalence of relevant diagnoses and laboratory abnormalities was similar in both groups. The most common lab abnormality was low hemoglobin. There was no statistically significant difference in incident adverse diagnoses/severe lab abnormalities with 300 mg versus 150 mg [incidence rate ratio (IRR): 1.51; 95% confidence interval (CI) 0.59--3.92). However, a statistically significant association was observed when gastrointestinal symptoms/moderate lab abnormalities were included in the outcome (IRR: 3.07, 95% CI 1.12--8.40).

Conclusion: As 3TC is a well tolerated drug with a wide therapeutic window, dose adjustment may be unnecessary among PWH with eGFR between at least 30 and 49 ml/min per 1.73 m2 or less. Clinical judgement is key when weighing the risks and benefits of 3TC dose adjustment for PWH experiencing gastrointestinal symptoms or moderate lab abnormalities.

PubMed Disclaimer

Comment in

References

    1. Coates JA, Cammack N, Jenkinson HJ, Mutton IM, Pearson BA, Storer R, et al. The separated enantiomers of 2’-deoxy-3’-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro . Antimicrob Agents Chemother 1992; 36:202–205.
    1. Schinazi RF, Chu CK, Peck A, McMillan A, Mathis R, Cannon D, et al. Activities of the four optical isomers of 2’,3’-dideoxy-3’-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes . Antimicrob Agents Chemother 1992; 36:672–676.
    1. Soudeyns H, Yao XI, Gao Q, Belleau B, Kraus JL, Nguyen-Ba N, et al. Antihuman immunodeficiency virus type 1 activity and in vitro toxicity of 2’-deoxy-3’-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog . Antimicrob Agents Chemother 1991; 35:1386–1390.
    1. Pluda JM, Cooley TP, Montaner JS, Shay LE, Reinhalter NE, Warthan SN, et al. A phase I/II study of 2’-deoxy-3’-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection . J Infect Dis 1995; 171:1438–1447.
    1. van Leeuwen R, Katlama C, Kitchen V, Boucher CA, Tubiana R, McBride M, et al. Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study . J Infect Dis 1995; 171:1166–1171.

Publication types

LinkOut - more resources